Total Payments
$640,807
2024 Payments
$185,900
Companies
12
Transactions
136
Medicare Patients
605
Medicare Billing
$80,312
Payment Breakdown by Category
Research$561,820 (87.7%)
Consulting$42,768 (6.7%)
Other$25,583 (4.0%)
Travel$7,267 (1.1%)
Food & Beverage$3,357 (0.5%)
Education$12.25 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $561,820 | 27 | 87.7% |
| Consulting Fee | $42,768 | 16 | 6.7% |
| Honoraria | $19,214 | 6 | 3.0% |
| Travel and Lodging | $7,267 | 30 | 1.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,369 | 2 | 1.0% |
| Food and Beverage | $3,357 | 54 | 0.5% |
| Education | $12.25 | 1 | 0.0% |
Payments by Type
Research
$561,820
27 transactions
General
$78,987
109 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neurocrine Biosciences, Inc. | $581,176 | 76 | $0 (2024) |
| RECORDATI_RARE_DISEASES_INC. | $21,437 | 12 | $0 (2024) |
| Corcept Therapeutics | $13,688 | 26 | $0 (2024) |
| Xeris Pharmaceuticals, Inc. | $11,714 | 3 | $0 (2024) |
| Amryt Pharma Holdings Ltd | $2,844 | 2 | $0 (2022) |
| Novo Nordisk Inc | $2,720 | 2 | $0 (2020) |
| Progenics Pharmaceuticals, Inc. | $2,169 | 1 | $0 (2023) |
| Novo Nordisk AS | $1,990 | 10 | $0 (2019) |
| Strongbridge US INC. | $1,800 | 1 | $0 (2020) |
| PFIZER INC. | $1,185 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $185,900 | 50 | Neurocrine Biosciences, Inc. ($156,394) |
| 2023 | $428,738 | 32 | Neurocrine Biosciences, Inc. ($418,726) |
| 2022 | $9,428 | 18 | Neurocrine Biosciences, Inc. ($5,988) |
| 2021 | $2,783 | 7 | RECORDATI_RARE_DISEASES_INC. ($2,481) |
| 2020 | $5,445 | 5 | Novo Nordisk Inc ($2,720) |
| 2019 | $8,513 | 24 | Corcept Therapeutics ($5,280) |
All Payment Transactions
136 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $169.86 | General |
| 11/19/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $8,656.75 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 11/18/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Education | In-kind items and services | $12.25 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 10/22/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $24,539.46 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 10/22/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $5,835.40 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 10/17/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Consulting Fee | Cash or cash equivalent | $5,850.00 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 10/07/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $24,825.35 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 08/19/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $12,860.06 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 07/15/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | Honoraria | Cash or cash equivalent | $610.00 | General |
| Category: ENDOCRINE AGENT | ||||||
| 07/01/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $28,222.20 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 06/17/2024 | RECORDATI_RARE_DISEASES_INC. | ISTURISA (Drug) | Honoraria | Cash or cash equivalent | $4,880.00 | General |
| Category: ENDOCRINE AGENT | ||||||
| 06/17/2024 | RECORDATI_RARE_DISEASES_INC. | ISTURISA (Drug) | Travel and Lodging | Cash or cash equivalent | $361.00 | General |
| Category: ENDOCRINE AGENT | ||||||
| 06/10/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $12,953.07 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 06/03/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $148.40 | General |
| 06/03/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $89.05 | General |
| 05/31/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $110.14 | General |
| Category: Endocrinology | ||||||
| 05/31/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Endocrinology | ||||||
| 05/31/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $41.27 | General |
| Category: Endocrinology | ||||||
| 05/31/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: Endocrinology | ||||||
| 05/23/2024 | RECORDATI_RARE_DISEASES_INC. | ISTURISA (Drug) | Honoraria | Cash or cash equivalent | $8,845.00 | General |
| Category: ENDOCRINE AGENT | ||||||
| 05/23/2024 | RECORDATI_RARE_DISEASES_INC. | ISTURISA (Drug) | Travel and Lodging | Cash or cash equivalent | $303.00 | General |
| Category: ENDOCRINE AGENT | ||||||
| 05/22/2024 | Corcept Therapeutics | Korlym (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,469.00 | General |
| Category: Endocrinology | ||||||
| 05/10/2024 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,999.00 | General |
| 04/22/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $10,141.83 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 04/22/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | Neurocrine BioSciences, Inc. | $412,177 | 14 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | Neurocrine BioSciences Inc. | $149,574 | 12 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | Neurocrine Biosciences, Inc. | $69.12 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 142 | 164 | $75,656 | $20,412 |
| 2022 | 3 | 129 | 158 | $71,832 | $18,694 |
| 2021 | 4 | 139 | 163 | $66,528 | $18,961 |
| 2020 | 6 | 195 | 224 | $85,822 | $22,245 |
Total Patients
605
Total Services
709
Medicare Billing
$80,312
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 51 | 67 | $31,088 | $8,748 | 28.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 56 | 62 | $21,328 | $6,080 | 28.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 35 | 35 | $23,240 | $5,584 | 24.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 44 | 63 | $29,232 | $7,716 | 26.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 54 | 64 | $22,016 | $5,653 | 25.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 31 | 31 | $20,584 | $5,325 | 25.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 35 | 47 | $21,808 | $5,766 | 26.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 54 | 60 | $20,640 | $5,718 | 27.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 30 | 30 | $19,920 | $4,953 | 24.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 20 | 26 | $4,160 | $2,524 | 60.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 44 | 53 | $24,592 | $5,978 | 24.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 51 | 66 | $22,704 | $5,533 | 24.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 31 | 31 | $20,584 | $5,033 | 24.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 24 | 26 | $4,160 | $2,348 | 56.4% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 18 | 18 | $9,594 | $2,074 | 21.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 13 | 13 | $2,080 | $716.68 | 34.5% |
| 98968 | Telephone assessment and management service, 21-30 minutes of medical discussion | Office | 2020 | 14 | 17 | $2,108 | $562.62 | 26.7% |
About Dr. Oksana Hamidi, D.O
Dr. Oksana Hamidi, D.O is a Endocrinology, Diabetes & Metabolism healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/18/2012. The National Provider Identifier (NPI) number assigned to this provider is 1629331400.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Oksana Hamidi, D.O has received a total of $640,807 in payments from pharmaceutical and medical device companies, with $185,900 received in 2024. These payments were reported across 136 transactions from 12 companies. The most common payment nature is "" ($561,820).
As a Medicare-enrolled provider, Hamidi has provided services to 605 Medicare beneficiaries, totaling 709 services with total Medicare billing of $80,312. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Dallas, TX
- Active Since 06/18/2012
- Last Updated 05/15/2019
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1629331400
Products in Payments
- ISTURISA (Drug) $15,271
- Korlym (Drug) $13,456
- RECORLEV (Drug) $11,714
- OSILODROSTAT (Drug) $3,660
- MYCAPSSA (Drug) $2,844
- Norditropin (Biological) $2,720
- AZEDRA (Drug) $2,169
- SOMAVERT (Drug) $1,185
- Ozempic (Drug) $1,041
- EVENITY (Biological) $25.44
- SIGNIFOR LAR (Drug) $24.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Dallas
Dr. Julio Rosenstock, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $2.4M
Endocrinology, Diabetes & Metabolism $2.4M
Steve Fordan, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $1.8M
Endocrinology, Diabetes & Metabolism $1.8M
Saleemah Fahmi, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $1.3M
Endocrinology, Diabetes & Metabolism $1.3M
Ildiko Lingvay, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $816,084
Endocrinology, Diabetes & Metabolism $816,084
Dr. Rajiv Dattatreya, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $782,699
Endocrinology, Diabetes & Metabolism $782,699
Dr. Luigi Meneghini, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $426,166
Endocrinology, Diabetes & Metabolism $426,166